Cancer Metabolism Based Therapeutics?

6 Posts | Page(s): 1 

Cancer Metabolism Based Therapeutics?

by ppres74 on Mon Oct 21, 2019 07:39 PM

Quote | Reply

Is anyone currently participating in clinical trials for their pancreatic cancer? There are currently some trials available of CPI-613 (devimistat) and FOLFORINOX that look promising. Does anyone have experience with therapeutics focused on the slowing the rate of cancer metabolism? 

RE: Cancer Metabolism Based Therapeutics?

by ppres74 on Mon Oct 21, 2019 07:39 PM

Quote | Reply

On Oct 21, 2019 7:39 PM ppres74 wrote:

Is anyone currently participating in clinical trials for their pancreatic cancer? There are currently some trials available of CPI-613 (devimistat) and FOLFORINOX that look promising. Does anyone have experience with therapeutics focused on the slowing the rate of cancer metabolism? 

https://rafaelpharma.com/rafael-study-connect/trials/panc003

RE: Cancer Metabolism Based Therapeutics?

by Treasure on Thu Oct 24, 2019 07:05 PM

Quote | Reply

Folfirinox is a very agressive treatment and for me, worked really well !

RE: Cancer Metabolism Based Therapeutics?

by ppres74 on Thu Oct 24, 2019 07:07 PM

Quote | Reply

How long was your treatment?

RE: Cancer Metabolism Based Therapeutics?

by dumbcritic on Thu Oct 24, 2019 07:15 PM

Quote | Reply

The combination of mFOLFIRINOX plus Devimistat was compared to historical data and improved the median progression-free survival by 55% (6.4 months to 9.9), median overall survival by 79% (11.1 to 19.9), the overall response rate (tumour shrinkage) by 93% and the median duration of response by 56% (5.9 to 9.2).

RE: Cancer Metabolism Based Therapeutics?

by Treasure on Fri Oct 25, 2019 10:06 PM

Quote | Reply

6 months, but at 5 months, there was no evidence of cancer, but I did the extra 2 treatments as a precautionary measure. Life is great!

6 Posts | Page(s): 1 
Subscribe to this message board discussion

Latest Messages

View More

We care about your feedback. Let us know how we can improve your CancerCompass experience.